Preventive Effect of Pretreatment with Pitavastatin on Contrast-Induced Nephropathy in Patients with Renal Dysfunction Undergoing Coronary Procedure: PRINCIPLE-II Randomized Clinical Trial

Woong Chol Kang, Minsu Kim, Sang Min Park, Byeong-Keuk Kim, Byoung-Kwon Lee, Hyuck Moon Kwon, Woong Chol Kang, Minsu Kim, Sang Min Park, Byeong-Keuk Kim, Byoung-Kwon Lee, Hyuck Moon Kwon

Abstract

This study aimed to evaluate the efficacy of pitavastatin pretreatment on contrast-induced nephropathy (CIN) in patients with chronic kidney disease (CKD) after a coronary procedure. This was a prospective, randomized, double-blinded, placebo-controlled, multicenter clinical trial. All consecutive 70 patients with CKD (eGFR < 60 mL/min/1.73 m2) were enrolled and randomized into two groups. Group I consisted of patients who were treated with statins (pitavastatin 4 mg/day) for seven days before and three days after the procedure (n = 37, 52.9%), and group II consisted of patients who were treated with a placebo (n = 33, 47.1%). The primary endpoint was the incidence of CIN, and the secondary endpoints were the change in serum creatinine (∆sCr) level and estimated glomerular filtration rate (∆eGFR) after the procedure. The mean age of the patients (males, 74%) was 70.4 ± 9.0 years. After the coronary procedure, the incidence of CIN was lower in group I than in group II, but the difference was not significant (5.4% vs. 9.1%, p = 0.661). The maximal ∆sCr was lower and the maximal ∆eGFR was higher in group I than in group II, but the difference was not significant (-0.11 ± 0.53 mg/dL and -0.04 ± 0.33 mg/dL, p = 0.678; 4.3 ± 11.2 mL/min/1.73 m2 and -2.9 ± 20.4 mL/min/1.73 m2, p = 0.161, respectively). This study showed the possibility of a clinical benefit of pretreatment with a high dose of pitavastatin for the prevention of CIN in patients with CKD after coronary procedure (ClinicalTrials.gov Identifier: NCT01871792).

Keywords: chronic kidney disease; contrast-induced nephropathy; pitavastatin.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Patient flowchart.
Figure 2
Figure 2
Primary endpoint: CIN occurrence.
Figure 3
Figure 3
Potential mechanisms of beneficial effects of statins on the CIN. NO: nitric oxide.

References

    1. McCullough P.A., Adam A., Becker C.R., Davidson C., Lameire N., Stacul F., Tumlin J., CIN Consensus Working Panel Epidemiology and prognostic implications of contrast-induced nephropathy. Am. J. Cardiol. 2006;98:5K–13K. doi: 10.1016/j.amjcard.2006.01.019.
    1. Mehran R., Aymong E.D., Nikolsky E., Lasic Z., Iakovou I., Fahy M., Mintz G.S., Lansky A.J., Moses J.W., Stone G.W., et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J. Am. Coll. Cardiol. 2004;44:1393–1399. doi: 10.1016/j.jacc.2004.06.068.
    1. Seeliger E., Sendeski M., Rihal C.S., Persson P.B. Contrast-induced kidney injury: Mechanisms, risk factors, and prevention. Eur. Heart J. 2012;33:2007–2015. doi: 10.1093/eurheartj/ehr494.
    1. John S., Schneider M.P., Delles C., Jacobi J., Schmieder R.E. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am. Heart J. 2005;149:473. doi: 10.1016/j.ahj.2004.06.027.
    1. Persson P.B., Hansell P., Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int. 2005;68:14–22. doi: 10.1111/j.1523-1755.2005.00377.x.
    1. Tumlin J., Stacul F., Adam A., Becker C.R., Davidson C., Lameire N., McCullough P.A., CIN Consensus Working Panel Pathophysiology of contrast-induced nephropathy. Am. J. Cardiol. 2006;98:14K–20K. doi: 10.1016/j.amjcard.2006.01.020.
    1. Attallah N., Yassine L., Musial J., Yee J., Fisher K. The potential role of statins in contrast nephropathy. Clin. Nephrol. 2004;62:273–278. doi: 10.5414/CNP62273.
    1. Ridker P.M., Rifai N., Clearfield M., Downs J.R., Weis S.E., Miles J.S., Gotto A.M., Jr., Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med. 2001;344:1959–1965. doi: 10.1056/NEJM200106283442601.
    1. Han Y., Zhu G., Han L., Hou F., Huang W., Liu H., Gan J., Jiang T., Li X., Wang W., et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J. Am. Coll. Cardiol. 2014;63:62–70. doi: 10.1016/j.jacc.2013.09.017.
    1. Jo S.H., Koo B.K., Park J.S., Kang H.J., Cho Y.S., Kim Y.J., Youn T.J., Chung W.Y., Chae I.H., Choi D.J., et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial—A randomized controlled study. Am. Heart J. 2008;155:e491–e498. doi: 10.1016/j.ahj.2007.11.042.
    1. Liang M., Yang S., Fu N. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials. Medicine. 2017;96:e7384. doi: 10.1097/MD.0000000000007384.
    1. Toso A., Maioli M., Leoncini M., Gallopin M., Tedeschi D., Micheletti C., Manzone C., Amato M., Bellandi F. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am. J. Cardiol. 2010;105:288–292. doi: 10.1016/j.amjcard.2009.09.026.
    1. Yang Y., Wu Y.X., Hu Y.Z. Rosuvastatin Treatment for Preventing Contrast-Induced Acute Kidney Injury after Cardiac Catheterization: A Meta-Analysis of Randomized Controlled Trials. Medicine. 2015;94:e1226. doi: 10.1097/MD.0000000000001226.
    1. Katsiki N., Mikhailidis D.P., Banach M. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opin. Pharmacother. 2019;20:2007–2017. doi: 10.1080/14656566.2019.1649394.
    1. Severino P., D’Amato A., Pucci M., Infusino F., Adamo F., Birtolo L.I., Netti L., Montefusco G., Chimenti C., Lavalle C., et al. Ischemic Heart Disease Pathophysiology Paradigms Overview: From Plaque Activation to Microvascular Dysfunction. Int. J. Mol. Sci. 2020;21:8118. doi: 10.3390/ijms21218118.
    1. Severino P., D’Amato A., Pucci M., Infusino F., Birtolo L.I., Mariani M.V., Lavalle C., Maestrini V., Mancone M., Fedele F. Ischemic Heart Disease and Heart Failure: Role of Coronary Ion Channels. Int. J. Mol. Sci. 2020;21:3167. doi: 10.3390/ijms21093167.
    1. Liu Y., Liu Y.H., Tan N., Chen J.Y., Zhou Y.L., Li L.W., Duan C.Y., Chen P.Y., Luo J.F., Li H.L., et al. Comparison of the efficacy of rosuvastatin versus atorvastatin in preventing contrast induced nephropathy in patient with chronic kidney disease undergoing percutaneous coronary intervention. PLoS ONE. 2014;9:e111124. doi: 10.1371/journal.pone.0111124.
    1. Liu P.Y., Lin L.Y., Lin H.J., Hsia C.H., Hung Y.R., Yeh H.I., Wu T.C., Chen J.Y., Chien K.L., Chen J.W. Pitavastatin and Atorvastatin double-blind randomized comPArative study among hiGh-risk patients, including thOse with Type 2 diabetes mellitus, in Taiwan (PAPAGO-T Study) PLoS ONE. 2013;8:e76298. doi: 10.1371/journal.pone.0076298.
    1. Ose L., Budinski D., Hounslow N., Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr. Med. Res. Opin. 2009;25:2755–2764. doi: 10.1185/03007990903290886.
    1. Eriksson M., Budinski D., Hounslow N. Long-term efficacy of pitavastatin versus simvastatin. Adv. Ther. 2011;28:799–810. doi: 10.1007/s12325-011-0057-6.
    1. Sponseller C.A., Morgan R.E., Kryzhanovski V.A., Campbell S.E., Davidson M.H. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: A Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial. Clin. Ther. 2014;36:1211–1222. doi: 10.1016/j.clinthera.2014.06.009.
    1. Teramoto T. Pitavastatin: Clinical effects from the LIVES Study. Atheroscler. Suppl. 2011;12:285–288. doi: 10.1016/S1567-5688(11)70888-1.
    1. Yokote K., Shimano H., Urashima M., Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. Expert Rev. Cardiovasc. Ther. 2011;9:555–562. doi: 10.1586/erc.11.47.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere